Get the Stockscreener App
1.34
2.19%
-0.03
Pulmatrix Inc stock is traded at $1.34, with a volume of 23,054.
It is down -2.19% in the last 24 hours and down -4.29% over the past month.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
See More
Previous Close:
$1.37
Open:
$1.4
24h Volume:
23,054
Relative Volume:
0.47
Market Cap:
$4.89M
Revenue:
$3,000
Net Income/Loss:
$-5.16M
P/E Ratio:
-0.9481
EPS:
-1.4133
Net Cash Flow:
$-5.43M
1W Performance:
+7.20%
1M Performance:
-4.29%
6M Performance:
-71.49%
1Y Performance:
-79.19%
1-Day Range:
$1.30
$1.40
1-Week Range:
$1.2201
$1.41
52-Week Range:
$1.16
$9.37
Pulmatrix Inc Stock (PULM) Company Profile
Name
Pulmatrix Inc
Sector
Industry
Phone
(888) 355-4440
Address
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
1.34 | 5.00M | 3,000 | -5.16M | -5.43M | -1.4133 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-18 | Initiated | H.C. Wainwright | Buy |
Pulmatrix Inc Stock (PULM) Latest News
Pulmatrix Q2 2025 Earnings: Loss Per Share Widens Amidst No Revenue DisclosureSocial Trade Signals - Newser
Pulmatrix Q2 2025 Earnings: Clinical-Stage Biotech Posts Net Loss of $0.42 per Share, Stock Rises 7.87%Community Buy Alerts - newser.com
Pulmatrix (PULM) Reports Predictable Q2 2025 — EPS $-0.42 On TargetTrading Community - Newser
Pulmatrix, Inc. Q1 2026 10-Q Report: Financial Results, Merger with Eos SENOLYTIX, and Going Concern Risks - Minichart
Pulmatrix Releases Q1 2026 Financial Results - AlphaStreet
Press Release: Pulmatrix Announces First Quarter 2026 Financial Results - Moomoo
Pulmatrix Announces Q1 2026 Financial Results and Merger Agreement with Eos SENOLYTIX - Minichart
PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M - TradingView
Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) — 10-Q Summary - TradingView
Pulmatrix Q1 net loss narrows, clinical development on hold - TradingView
Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX - TradingView
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution - Stock Titan
Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan - Stock Titan
Pulmatrix Announces First Quarter 2026 Financial Results - PR Newswire
TradingKey - TradingKey
Number of shareholders of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
The hidden strength in Pulmatrix (PULM) most investors miss (Volatility Increases) 2026-05-08Attention Stocks - newser.com
The hidden strength in Pulmatrix (PULM) most investors miss (Risk Aversion) 2026-05-08Crowd Entry Points - newser.com
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets - Quantisnow
Pulmatrix (PULM) Stock: Is It Losing Market Strength |Shared Buy Zones - Newser
Eos-backed investor takes 9.99% Pulmatrix (PULM) stake ahead merger - Stock Titan
PULM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulmatrix, Inc. announced that it has received $1 million in funding - marketscreener.com
Pulmatrix closes $1M preferred stock placement with Eos affiliate - Investing.com
Pulmatrix Closes $1M Series B Preferred Stock Investment at $2.20 per Share as Part of Planned Merger with Eos SENOLYTIX 1 - Minichart
Pulmatrix announces closing of preferred stock transaction as part of planned merger - marketscreener.com
Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger - TradingView
Pulmatrix closes $1M preferred stock placement with Eos affiliate By Investing.com - Investing.com Canada
Pulmatrix Raises $1M in Preferred Stock Financing - TipRanks
Pulmatrix closes $1M Series B preferred private placement tied to planned merger - TradingView
Pulmatrix (NASDAQ: PULM) closes $1M Series B preferred tied to Eos merger - Stock Titan
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger - PR Newswire
Pulmatrix (PULM) Stock: Why Working Capital (Trades Higher) 2026-04-20Fibonacci Analysis - Cổng thông tin điện tử tỉnh Lào Cai
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders - The AI Journal
Momentum Shift: Is Pulmatrix Inc in a consolidation phase2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
If You Invested $1,000 in Pulmatrix (PULM) - Stock Titan
Stock Recap: Will Pulmatrix Inc benefit from current market trends2026 Historical Comparison & Verified High Yield Trade Plans - baoquankhu1.vn
Gains Report: Will Pulmatrix Inc benefit from seasonality2026 Technical Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Is Pulmatrix (PULM) Stock Good for Beginners | Price at $1.26, Down 4.55%Certified Trade Ideas - Newser
Is Pulmatrix (PULM) Stock Good for Long Term | Price at $1.35, Up 3.05%Overnight Profile - Newser
PULM Stock Analysis: Pulmatrix Inc. Biotech At $1.31 Post Minor Daily Decline - Newser
FOMO Trade: Will Pulmatrix Inc benefit from current market trendsQuarterly Trade Review & Consistent Income Trade Recommendations - baoquankhu1.vn
FRA:2PU PB Ratio: 1.34 — 15% Above Median - GuruFocus
Pulmatrix and Eos SENOLYTIX Announce $19 Million Merger to Advance Mitochondrial Therapies - Global Legal Chronicle
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
Ideas Watch: Is Pulmatrix Inc in a consolidation phaseQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Pulmatrix and Eos SENOLYTIX Announce $19M Merger to Advance AI-Driven Mitochondrial Therapies for Sarcopenia and Aging-Related Diseases 1 - Minichart
Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq - tipranks.com
Pulmatrix to Merge With Eos SENOLYTIX; Raises $1M Preferred, Eos Secures Up to $18M - TradingView
Pulmatrix (PULM) plans reverse merger with Eos SENOLYTIX, legacy holders keep ~6% - Stock Titan
Pulmatrix Inc Stock (PULM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):